3985A Sorrento Valley Boulevard
San Diego, CA 92121
Ph: (858) 450-9595
Fax: (858) 450-0544
Email: hr@paxvax.com

Company Overview

PaxVax is an exciting and fast-paced vaccine start-up company developing candidate oral vaccines for influenza, and other key infectious diseases. PaxVax has developed a novel and proprietary oral vaccine technology based on a common virus called adenovirus. This technology removes the delivery hurdles of traditional injectable vaccines, namely the need for cold storage, needles, and administration by medical personnel.

• Oral tablets can be easily stored and distributed at room temperature, and self-administered
• PaxVax’s vaccines can also be produced in record speed, in large quantities, and at low expense compared to traditional egg-based vaccines such as those against seasonal or pandemic flu (influenza)
• Vaccination by the oral route rather than injection may yield a more robust immune response (B cells and T cells) and may enable vaccination against diseases that have historically been intransigent to traditional vaccine development methods

Based on these competitive advantages, PaxVax anticipates becoming a major player in the world flu vaccine market of $1.5 billion and dramatically altering the market by delivering its flu vaccine to the developing world which today can neither afford nor access injectable flu vaccines. PaxVax also intends to sell stockpiles of a vaccine specifically against H5N1 or “bird flu” to governments to protect against a worldwide pandemic. More importantly, PaxVax technology is not limited to flu but can be extended to address several infectious disease needs and markets.

Global Impact

PaxVax intends to develop vaccine candidates against influenza, HPV, malaria, and HIV. These vaccine candidates target some of the world’s greatest infectious disease killers, and represent multi-billion dollar markets worldwide. PaxVax will seek financial support and leverage for these additional products from Non-Government Organizations (NGOs) such as the Wellcome Trust and Government agencies such as the National Institutes of Health. PaxVax also plans to have a sister non-profit 501c3 organization to support clinical trials and the establishment of manufacturing plants in the Third World.

Technical Progress

PaxVax and its collaborators have already demonstrated the viability of various pieces of its oral adenovirus-based vaccine technology:

• Adenovirus has been used for vaccination in millions of U.S. military recruits
• Antigens from flu, HPV, and HIV have been inserted into adenovirus vectors
• Adenovirus vectors have been manufactured at scale (to FDA quality standards)
• Similar virus vectors have been formulated to be room temperature stable
• Adenovirus vectors have been packaged into enteric coated tablets or pills

Management Team

• Kenneth Kelley, Chairman and Chief Executive Officer
  Mr. Kelley has backed over 24 startups as a venture capitalist mainly with Institutional Venture Partners (IVP), including 18 IPO’s. He founded and served as CEO of IntraBiotics, an antibiotic company (NASDAQ IPO). He serves as Chairman of the Board of Halozyme Therapeutics (HALO) and venture backed MPEX Pharmaceuticals, both in San Diego, California.
• Deborah Mosca, Ph.D. - Vice President Project Management
  Dr. Mosca has over 27 years of experience in the discovery and development of novel therapeutics for infectious diseases at large pharma (Lederle), biotech (IntraBiotics, Elitra and Nereus), and non-profit research organizations (TSRI).
• Paul Shabram, – Vice President Manufacturing
  Mr. Shabram has developed GMP manufacturing processes of adenovirus vectors in the past for Canji and Schering-Plough.
• Janine M. Taylor – Chief Financial Officer
  Ms. Taylor has over 20 years of financial and operations experience in the biotech industry, and most recently served as a startup CFO and COO for Genicon Sciences and Applied Molecular Evolution.

Contact: Please email resumes to: hr@paxvax.com